keyword
https://read.qxmd.com/read/35101266/three-dose-versus-four-dose-primary-schedules-for-tick-borne-encephalitis-tbe-vaccine-fsme-immun-for-those-aged-50-years-or-older-a-single-centre-open-label-randomized-controlled-trial
#1
RANDOMIZED CONTROLLED TRIAL
Anu Kantele, Lars Rombo, Sirkka Vene, Michael Kundi, Lars Lindquist, Elina O Erra
BACKGROUND: TBE vaccination failures among those past middle age have raised concern about immune response declining with age. We investigated immunogenicity of the TBE-vaccine FSME-Immun among those aged 50+ years using the standard three-dose primary series and alternative four-dose schedules. METHODS: In this single-centre, open-label, randomized controlled trial, 200 TBE-naive Swedish adults were given primary TBE vaccination with FSME-Immun. Those aged 50+ years (n = 150) were randomized to receive the standard three-dose (days 0-30-360) or one of two four-dose series (0-7-21-360; 0-30-90-360)...
February 23, 2022: Vaccine
https://read.qxmd.com/read/31924650/magnitude-and-functional-profile-of-the-human-cd4-t-cell-response-throughout-primary-immunization-with-tick-borne-encephalitis-virus-vaccine
#2
JOURNAL ARTICLE
Renata Varnaitė, Kim Blom, Margit H Lampen, Sirkka Vene, Sarah Thunberg, Lars Lindquist, Hans-Gustaf Ljunggren, Lars Rombo, Helena H Askling, Sara Gredmark-Russ
Tick-borne encephalitis (TBE) is a viral infection of the CNS caused by TBE virus. With no specific treatment available, the only protection is a formalin-inactivated whole virus vaccine. Primary immunization with European TBE vaccines, as recommended by the manufacturers, consists of three vaccine doses administered within a 1-y period. Protection from vaccination is believed to be mediated by Abs, yet T cells may also have a protective role. We set out to characterize the human CD4+ T cell response throughout primary TBE immunization...
January 10, 2020: Journal of Immunology
https://read.qxmd.com/read/29386094/distinction-between-serological-responses-following-tick-borne-encephalitis-virus-tbev-infection-vs-vaccination-sweden-2017
#3
JOURNAL ARTICLE
Bo Albinsson, Sirkka Vene, Lars Rombo, Jonas Blomberg, Åke Lundkvist, Bengt Rönnberg
Tick-borne encephalitis virus (TBEV) is an important European vaccine-preventable pathogen. Discrimination of vaccine-induced antibodies from those elicited by infection is important. We studied anti-TBEV IgM/IgG responses, including avidity and neutralisation, by multiplex serology in 50 TBEV patients and 50 TBEV vaccinees. Infection induced antibodies reactive to both whole virus (WV) and non-structural protein 1 (NS1) in 48 clinical cases, whereas 47 TBEV vaccinees had WV, but not NS1 antibodies, enabling efficient discrimination of infection/vaccination...
January 2018: Euro Surveillance
https://read.qxmd.com/read/24176496/cross-protection-elicited-by-primary-and-booster-vaccinations-against-japanese-encephalitis-a-two-year-follow-up-study
#4
JOURNAL ARTICLE
Elina O Erra, Helena Hervius Askling, Sutee Yoksan, Lars Rombo, Jukka Riutta, Sirkka Vene, Lars Lindquist, Olli Vapalahti, Anu Kantele
BACKGROUND: The inactivated Vero cell-derived vaccine (JE-VC, IXIARO) has replaced the traditional mouse brain-derived preparations (JE-MB) in travelers' vaccinations against Japanese encephalitis. We showed recently that a single JE-VC dose efficiently boosts immunity in JE-MB-primed vaccinees, and that JE-VC elicits cross-protective immunity against non-vaccine genotypes, including the emerging genotype I. While these studies only provided short-term data, the present investigation evaluates the longevity of seroprotection in the same volunteers...
December 17, 2013: Vaccine
https://read.qxmd.com/read/23074319/cross-protective-capacity-of-japanese-encephalitis-je-vaccines-against-circulating-heterologous-je-virus-genotypes
#5
JOURNAL ARTICLE
Elina O Erra, Helena Hervius Askling, Sutee Yoksan, Lars Rombo, Jukka Riutta, Sirkka Vene, Lars Lindquist, Olli Vapalahti, Anu Kantele
Current Japanese encephalitis vaccines are derived from strains of genotype III, yet heterologous genotypes are emerging in endemic areas. Inactivated vaccines given to European travelers were found to elicit protective levels of neutralizing antibodies against heterologous strains of genotypes I-IV.
January 2013: Clinical Infectious Diseases
https://read.qxmd.com/read/22947427/proinflammatory-cytokines-in-serum-and-cerebrospinal-fluid-of-cidp-patients
#6
JOURNAL ARTICLE
Michael Rentzos, Aikaterini V Angeli, Antonis Rombos, Andreas Kyrozis, Chryssoula Nikolaou, Vassiliki Zouvelou, Aikaterini Dimitriou, Margarita Zoga, Maria-Eleni Evangelopoulos, Alexandra Tsatsi, Anthousa Tsoutsou, Ioannis Evdokimidis
INTRODUCTION: Little is known about the role of cytokines in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Interleukin (IL)-12 and IL-15 are the major growth and differentiation factors for Th-1 cells and IL-17 is a marker of Th-17 cell expansion and activation, a high proinflammatory new subset of T cells that induce severe autoimmunity. PATIENTS AND METHODS: We measured by enzyme-like immunosorbent assay serum and cerebrospinal fluid (CSF) levels of IL-15, IL-12, and IL-17 in 24 patients with CIDP and 12 patients with other non-inflammatory neurological disorders and serum levels in 16 healthy subjects...
November 2012: Neurological Research
https://read.qxmd.com/read/22696017/a-single-dose-of-vero-cell-derived-japanese-encephalitis-je-vaccine-ixiaro-effectively-boosts-immunity-in-travelers-primed-with-mouse-brain-derived-je-vaccines
#7
JOURNAL ARTICLE
Elina O Erra, Helena Hervius Askling, Lars Rombo, Jukka Riutta, Sirkka Vene, Sutee Yoksan, Lars Lindquist, Sari H Pakkanen, Eili Huhtamo, Olli Vapalahti, Anu Kantele
BACKGROUND: A significant part of the world population lives in areas with endemic Japanese encephalitis (JE). For travelers from nonendemic countries, Vero cell-derived vaccine (JE-VC; Ixiaro) has replaced traditional mouse brain-derived vaccines (JE-MB) associated with safety concerns. The 2 vaccines are derived from different viral strains: JE-VC from the SA14-14-2 strain and JE-MB from the Nakayama strain. No data exist regarding whether JE-VC can be used to boost immunity after a primary series of JE-MB; therefore, a primary series of JE-VC has been recommended to all travelers regardless of previous vaccination history...
September 2012: Clinical Infectious Diseases
https://read.qxmd.com/read/22122857/immunogenicity-of-delayed-tbe-vaccine-booster
#8
JOURNAL ARTICLE
H H Askling, S Vene, L Rombo, L Lindquist
Information is scarce regarding the antibody response when TBE-vaccine booster doses are delayed, which is a common situation in daily life. We have investigated the immune response after a delayed booster dose compared to a normal booster interval in an every-day setting. Overall, 250/260 (96%) of the study participants had neutralizing antibodies post-booster, with no significant difference between normal and delayed booster intervals. Based on our findings we propose that healthy individuals who have failed adherence to the recommended schedule of TBE-vaccination can be given a delayed dose without concern of immunogenicity...
January 11, 2012: Vaccine
https://read.qxmd.com/read/18976327/circulating-interleukin-10-and-interleukin-12-in-parkinson-s-disease
#9
JOURNAL ARTICLE
M Rentzos, C Nikolaou, E Andreadou, G P Paraskevas, A Rombos, M Zoga, A Tsoutsou, F Boufidou, E Kapaki, D Vassilopoulos
BACKGROUND: Interleukin (IL)-12 is a heterodimeric cytokine produced by activated blood monocytes, macrophages and glial cells. It enhances differentiation and proliferation of T cells and increases production of proinflammatory cytokines. IL-10 is a pleiotropic cytokine produced by both lymphocytes and mononuclear phagocytes including microglia. Recent studies demonstrated the neuroprotective effect of IL-10. There is little information about the involvement of IL-12 or IL-10 in the pathophysiology of Parkinson's disease (PD)...
May 2009: Acta Neurologica Scandinavica
https://read.qxmd.com/read/17986095/circulating-interleukin-15-and-rantes-chemokine-in-parkinson-s-disease
#10
JOURNAL ARTICLE
M Rentzos, C Nikolaou, E Andreadou, G P Paraskevas, A Rombos, M Zoga, A Tsoutsou, F Boufidou, E Kapaki, D Vassilopoulos
UNLABELLED: Interleukin-15 promotes T-cell proliferation, induction of cytolytic effector cells including natural killer (NK) and cytotoxic cells and stimulates B-cell to proliferate and secrete immunoglobulins. RANTES is a C-C beta chemokine with strong chemoattractant activity for T lymphocytes and monocytes. OBJECTIVES: The objective of our study was to find out whether IL-15 and RANTES are involved in the possible inflammatory reactions of PD. PATIENTS AND METHODS: We measured by immunoassay serum IL-15 and RANTES levels in 41 patients with PD in comparison with serum levels in 19 healthy subjects age and sex-matched...
December 2007: Acta Neurologica Scandinavica
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.